Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2006

View Archived Issues

ALS Association awards research funding to Sirtris

Safetek signs term sheet with Resdevco

Dynavax Technologies completes acquisition of Rhein Biotech GmbH

Apaziquone highly active in superficial bladder cancer

Teverelix shows promise in phase II prostate cancer study

Tolterodine improves overactive bladder symptoms and patient quality of life

SUNRISE study reveals urinary urgency improvement with solifenacin

hMaxi-K gene transfer for erectile dysfunction safe in phase I study

Dose proportionality confirmed with BEMA Fentanyl

Antinociceptive activity of neurotoxin receptor site 2-targeting sodium channel blocker

Disappointing results from phase III trial of bicifadine in chronic low back pain

IND approval for Aurora kinase inhibitor AT-9283

Phase II picoplatin study expanded into Eastern Europe

Panzem NCD with paclitaxel studied for metastatic breast cancer

DOD grant supports study of bavituximab in breast cancer

Enrollment completed in study of Chondrogen to repair tissue in the knee

PhytoMedical to focus on development of specific polyphenols

Series B financing at Protez to support development of PZ-601

Target enrollment completed in phase IIa study of E1-I.N.T. for type 2 diabetes

New Asian study for Iressa in first-line NSCLC

Lixivaptan demonstrates aquaretic effects in heart failure patients

ZT-1 evaluated in vivo, in healthy subjects and in Alzheimer's disease patients

European approval and recommendation for new Keppra indications

European approval for Preotact

Vaprisol launched for treatment of euvolemic hyponatremia

Roche seeks European approval for novel anemia drug CERA

Coagulation factor Xa inhibitors prepared and tested at Merck

Recent Bayer patent imparts novel agents for lipoprotein-related disorders

Two recent Pfizer patents describe new histamine H3 receptor antagonists

Newly formed Abraxis Bioscience presents data on nab tumor targeting technology